Patent · US Active

Growth hormone fusion proteins

US8293709B2 · kind B2 · utility

7Cited by

0References

18Claims

0Family size

Assignee

ASTERION LIMITED · GB

Inventors

Richard Ross · Weston, US
Peter Artymiuk · Sheffield, GB
Jon Sayers · Clay Cross, GB

Key dates

Filing date	Jul 16, 2008
Grant date	Oct 23, 2012
Priority date	—
Expiry date	Apr 27, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/31
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.